En español
NIDA

Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)

This is a 12-week, intent-to-treat, randomized controlled trial to evaluate the impact of N-Acetylcysteine (NAC) versus matched placebo (PBO) twice daily, added to compliance enhancement (CE) and contingency management (CM) interventions, on cannabis use among treatment-seeking adults.  The primary analysis will evaluate the impact of NAC versus PBO on cannabis use during the 12-week treatment intervention with the primary outcome measure being the proportion of negative urine cannabinoid tests submitted during active treatment, compared between the two treatment groups.

CTN Protocol ID: 
CTN-0053
Enrollment Status: 
Enrolling
Principal Investigator(s)
Kevin Gray, M.D.
Associate Professor
Medical University of South Carolina
125 Doughty Street, MSC861
Charleston, SC 29455
graykm@musc.edu

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.